IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) announces that it has applied for and received approval for the voluntary delisting of its common stock from the TSX Venture Exchange ( “TSXV”). It is therefore expected that as of the market close on Friday 25 November 2022, IPA common shares will no longer be listed or listed for trading on the TSXV.
The delisting of TSXV will have no effect on the Company’s listing on the NASDAQ Global Market (the “NASDAQ”). The common stock will continue to trade on the NASDAQ under the ticker symbol “IPA”.
The Company believes that the trading volume of its shares on the TSXV no longer justifies the expense and administrative effort required to maintain a dual listing. The Company also believes that the delisting from TSXV will create a central platform for its NASDAQ common stock, positively impacting the Company’s liquidity and shareholder value.
Following the delisting of TSXV, IPA shareholders will be able to trade their common stock through their brokers on the NASDAQ. Since most brokers in Canada, including many discount and online brokers, have the ability to buy and sell NASDAQ-listed stocks, the IPA listing on the NASDAQ will continue to provide shareholders with the same level of accessibility to trade stocks. ordinary of the Company. Shareholders with shares in Canadian brokerage accounts are encouraged to contact their brokers to confirm how to trade IPA shares on the NASDAQ.
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe, including such entities as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) BV (collectively, the “IPA Family”). The IPA Family is a biotherapeutic technology and research group leveraging systems biology, multi-omics modeling, and complex systems artificial intelligence to support its proprietary bioplatform-based antibody discovery technologies. These services include the discovery, development and licensing of highly specialized and comprehensive therapeutic biologics, supporting its business partners as they seek to discover and develop new biologics to combat the most complex targets. For more information, visit our website www.ipatherapeutics.com.
This press release contains forward-looking statements pursuant to applicable US and Canadian securities laws. Forward-looking statements are often identifiable by the use of words such as “potential”, “plans”, “hopes” or “not hopes”, “should”, “estimates”, “intends”, “anticipates or “does not anticipate”, or “believe”, or the use of other words and expressions or which indicate that certain measures, certain events or certain results “might”, “could”, “would”, “could”. maybe” or “will” be taken, take place or be reached. The forward-looking information contained in this press release includes, but is not limited to, statements regarding the timing of the delisting of the Common Shares on the TSXV, the anticipated benefits associated with the delisting on the TSXV, as well as future results, accessibility and ability to to trade the Company’s common stock on the NASDAQ and the early re-listing of the Company’s common stock on the NASDAQ. With respect to forward-looking information contained herein, IPA has provided such statements and information based on certain assumptions that management believed reasonable at the time.
The forward-looking information involves known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements declared herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a variety of factors and risks, including, without limitation, regulatory filings may not be filed or approved or may not be timely; that the ordinary shares of IPA can be delisted by the TSXV, or on the scheduled date; that trading of the Company’s common stock on the NASDAQ may not be available as anticipated; as well as the risks listed in the Company’s Annual Information Form of 28 July 2022 (available on the Company profile at the following address www.sedar.com) and on the Company’s Form 40-F, dated July 29, 2022 (available on the Company profile at www.sec.gov). If one or more of these risks or uncertainties materialize, or if assumptions underlying the forward-looking statements prove to be incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this press release. Readers are therefore cautioned not to place undue reliance on the forward-looking information contained in this press release.
Forward-looking statements contained in this press release are made as of the date of this press release and, accordingly, are subject to change after that date. The Company undertakes no obligation to update or revise any forward-looking statements, written or oral, that we may make or that we may make, except as required by applicable law.
Neither the TSX Venture Exchange nor its settlement service provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The text of the press release resulting from a translation must in no way be considered official. The only authentic version of the press release is that of the original language press release. The translation should always be compared with the source text, which will set a precedent.